[Lipids and acute coronary syndromes]

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Atherosclerosis Research

Context:

• Eccentric atherogenic plaques, causing minimal coronary artery narrowing, are responsible for 60-80% of acute coronary syndromes.
• Plaque vulnerability stems from macrophage-released cytokines, leading to fibrous capsule weakening, rupture, and intracoronary thrombosis.
• Existing studies (4S, LIPID, CARE, WOSCOPS, AFCAPS/TexCAPS) demonstrate statin efficacy in reducing cholesterol and cardiovascular events.

Purpose:

• To evaluate the role of statins in managing acute coronary syndromes and atherosclerosis.
• To understand the mechanisms of plaque instability and the impact of lipid-lowering therapies.
• To identify high-risk patient groups requiring aggressive or combined hypolipidemic treatment.

Summary:

• Statins significantly decrease total and LDL-cholesterol (20-35%), reducing relative risk of mortality and morbidity (20-40%) by preventing plaque progression and potentially causing regression.
• Statins exert extralipid effects that stabilize vulnerable plaques, crucial for preventing rupture and thrombosis.
• While effective, statins require optimization, especially for specific risk groups (e.g., high triglycerides, post-bypass patients), and combination therapies (statins/fibrates) may be necessary.

Impact:

• Statins are fundamental in reducing atherothrombotic risk, improving outcomes for patients with coronary artery disease.
• Understanding plaque dynamics and lipid profiles is key to tailoring treatment for diverse patient populations.
• Continued research and stricter therapeutic goals are essential to further reduce the high prospective mortality and morbidity in coronary patients.